About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Lrrc25em1Cya
endonuclease-mediated mutation 1, Cyagen Biosciences
MGI:6514757
Summary 1 genotype
Jump to Allelic Composition Genetic Background Genotype ID
hm1
Lrrc25em1Cya/Lrrc25em1Cya C57BL/6J-Lrrc25em1Cya/Cya MGI:6514758


Genotype
MGI:6514758
hm1
Allelic
Composition
Lrrc25em1Cya/Lrrc25em1Cya
Genetic
Background
C57BL/6J-Lrrc25em1Cya/Cya
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Lrrc25em1Cya mutation (0 available); any Lrrc25 mutation (18 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
homeostasis/metabolism
• mice subjected to aortic banding develop enhanced cardiac hypertrophy, cardiac fibrosis, cardiac inflammation, and accelerated cardiac dysfunction
• cardiomyocytes stimulated with angiotensin II show increased expression of TNF-alpha
• cardiomyocytes stimulated with angiotensin II show higher expression levels of TGF-beta1

cardiovascular system
• mice subjected to aortic banding exhibit accelerated cardiac hypertrophy compared to controls and show enhanced expression of cardiac hypertrophy markers
• mice subjected to aortic banding exhibit a higher ratio of heart weight to body weight compared to controls
• mice subjected to aortic banding exhibit enhanced collagen accumulation and enhanced expression of fibrosis markers
• cardiomyocytes stimulated with angiotensin II show exacerbated fibrosis compared to control cardiomyocytes
• mice subjected to aortic banding show decreased left ventricle ejection fraction and left ventricle fractional shortening
• mice subjected to aortic banding develop enhanced cardiac hypertrophy, cardiac fibrosis, cardiac inflammation, and accelerated cardiac dysfunction
• marker analysis indicates that aortic banding-induced inflammation is aggravated in mutants
• cardiomyocytes stimulated with angiotensin II show increased expression of TNF-alpha, IL-1beta, and p-NF-kappaB
• pre-treatment with Pirfenidone, a TGF-beta1 inhibitor, diminishes the angiotensin II-induced expression of TGF-beta1, p-NF-kappaB, TNF-alpha, and IL-1beta
• treatment of cardiomyocytes with BAY 11-7082, a suppressor of NF-kappaB activation, diminishes the angiotensin II-induced expression of p-NF-kappaB, TNF-alpha, and IL-1beta

growth/size/body
• mice subjected to aortic banding exhibit accelerated cardiac hypertrophy compared to controls and show enhanced expression of cardiac hypertrophy markers
• mice subjected to aortic banding exhibit a higher ratio of heart weight to body weight compared to controls

immune system
• marker analysis indicates that aortic banding-induced inflammation is aggravated in mutants
• cardiomyocytes stimulated with angiotensin II show increased expression of TNF-alpha, IL-1beta, and p-NF-kappaB
• pre-treatment with Pirfenidone, a TGF-beta1 inhibitor, diminishes the angiotensin II-induced expression of TGF-beta1, p-NF-kappaB, TNF-alpha, and IL-1beta
• treatment of cardiomyocytes with BAY 11-7082, a suppressor of NF-kappaB activation, diminishes the angiotensin II-induced expression of p-NF-kappaB, TNF-alpha, and IL-1beta
• cardiomyocytes stimulated with angiotensin II show increased expression of TNF-alpha

muscle
• mice subjected to aortic banding show decreased left ventricle ejection fraction and left ventricle fractional shortening





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
10/29/2024
MGI 6.24
The Jackson Laboratory